ARTICLE | Product Development
TIGIT breaks through as next-generation checkpoint target
ASCO preview: TIGIT’s dual role in immunity could position it to lead among next-gen checkpoints
May 23, 2020 3:25 AM UTC
Next-generation checkpoint inhibitors will take the limelight at the 2020 virtual ASCO meeting, with all eyes on TIGIT as the first to back up the noise with data. Genentech is poised to present Phase II data that positions TIGIT as the first next-generation checkpoint to deliver the clinical efficacy expected from preclinical models.
In an abstract released ahead of the American Society of Clinical Oncology’s Virtual Scientific Program, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) showed that its anti-TIGIT mAb tiragolumab had additive benefit when paired with a PD-L1 inhibitor, with no additional toxicity (see “TIGIT Emerges as a Standout”). ...